HC Wainwright Analysts Boost Earnings Estimates for RNTX

Rein Therapeutics Inc. (NASDAQ:RNTX) – Equities research analysts at HC Wainwright increased their Q2 2026 earnings per share estimates for shares of Rein Therapeutics in a research report issued to clients and investors on Monday, June 1st. HC Wainwright analyst B. Folkes now forecasts that the company will earn ($0.27) per share for the quarter, up from their prior estimate of ($0.49). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Rein Therapeutics’ current full-year earnings is ($1.63) per share. HC Wainwright also issued estimates for Rein Therapeutics’ Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at ($0.50) EPS, FY2028 earnings at ($0.66) EPS and FY2029 earnings at ($0.57) EPS.

Rein Therapeutics (NASDAQ:RNTX) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.30.

Separately, Wall Street Zen upgraded shares of Rein Therapeutics to a “sell” rating in a research note on Saturday, May 16th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $7.00.

Rein Therapeutics Stock Down 3.7%

Shares of RNTX stock opened at $1.03 on Wednesday. Rein Therapeutics has a 12 month low of $0.95 and a 12 month high of $2.18. The company’s fifty day simple moving average is $1.32 and its 200-day simple moving average is $1.30. The firm has a market cap of $88.11 million, a PE ratio of -0.54 and a beta of 1.35.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Voss Capital LP increased its holdings in shares of Rein Therapeutics by 86.0% during the 3rd quarter. Voss Capital LP now owns 2,666,532 shares of the company’s stock worth $3,053,000 after acquiring an additional 1,232,846 shares during the last quarter. Geode Capital Management LLC acquired a new stake in Rein Therapeutics during the 2nd quarter valued at $344,000. State Street Corp boosted its position in Rein Therapeutics by 374.3% during the fourth quarter. State Street Corp now owns 75,904 shares of the company’s stock worth $88,000 after purchasing an additional 59,900 shares during the period. Jane Street Group LLC bought a new position in Rein Therapeutics during the fourth quarter worth $72,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in shares of Rein Therapeutics in the second quarter valued at $68,000. 90.89% of the stock is currently owned by institutional investors.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.